Antibacterial play Entasis raises $50M series B

Entasis Therapeutics Inc. (Waltham, Mass.) raised $50 million in a series B round led by new investor Clarus Ventures. Frazier Healthcare Partners, Novo A/S (Hellerup, Denmark) and Eventide Funds also participated.

Entasis' lead program is ETX0914 ( AZD0914), a benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae. The oral antibiotic is in Phase II testing to treat uncomplicated gonorrhea. ...